Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2026)

Revolution Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $238.7 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 27216.25% year-over-year to $238.7 million in Q1 2026; TTM through Mar 2026 was $859.4 million, a 10.43% decrease from a year earlier, with the FY2025 full-year figure at $621.5 million, down 35.22% from the prior year.
• Cash from Financing Activities eased to $238.7 million in Q1 2026 per RVMD's latest filing, from $365.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $873.8 million in Q4 2024 and bottomed at -$1.6 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $64.6 million (2023), against an average of $197.1 million.
• Across the five-year window, Cash from Financing Activities jumped 106196.72% in 2023 and tumbled 102.06% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $51.4 million in 2022, then jumped by 1534.16% to $839.4 million in 2023, then advanced by 4.1% to $873.8 million in 2024, then plunged by 58.15% to $365.7 million in 2025, then sank by 34.71% to $238.7 million in 2026.
• Per Business Quant, the three latest RVMD Cash from Financing Activities figures stand at $238.7 million (Q1 2026), $365.7 million (Q4 2025), and -$1.6 million (Q3 2025).